Cannara Biotech Company Spotlight
In this episode, David Flores sits down with Cannara CFO Nicholas Sosiak, to discuss the Company's future goals and to spotlight what differentiates Cannara from other companies in the cannabis space.
Similar Posts
Interview with Julianne Keu, Psychedelic YouTuber
In this episode, YouTuber Julianne Keu discusses how she went from microdosing psilocybin to participating in shamanic doses to explore the mystical and spiritual universe.
Interview With Pierre Bouchard
Psychotherapist, Pierre Bouchard talks with our Director of Content, Jill Ettinger.
The Spotlight Round Up Video, March 31st
As we continue to strive to be the leading source for news and unique perspective within the emerging sector of medicinal psychedelics, we are excited to debut the Spotlight Roundup! This video series, produced in collaboration with Elk’s Pride Pictures, provides a concise and informative roundup related to some of the most important news developments happening within this rapidly expanding industry. From the latest IPO’s, to new clinical trials, the Spotlight Roundup covers everything you need to know!
Cathie Wood and ARK Invest Buy a Psychedelic Stock!!! | $ARKG | Initial Reaction 🍄🍾
GUYS. IT HAPPENED. Cathie Wood and ARK Invest have invested in a Psychedelic Stock! Specifically, ARKG, or the ARK Genomic Revolution ETF have purchased atai Life Sciences (Nasdaq: atai)!
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Last year, the Psychedelic Investor and the Reddit Page “ShroomStocks” managed to get the question of “would you ever invest in Psychedelic Stocks” asked to Cathie Wood of ARK Invest, and her answer was a dismissive NO. She said that ARK did not invest in binary stocks, though Kevin O’Leary, who was on the same panel disagreed.
Well, it seems that time (and maybe Kevin O’Leary) have changed her mind. On Wednesday, February 9th, it was revealed that the Ark Genomic Revolution ETF, ticker symbol ARKG, had purchased 83,278 shares of ATAI.
And while this only represents 0.01% of that fund’s total holdings, it does represent a big moment for the entire psychedelics industry. For better or worse, Cathie Wood has a huge voice among investors who like growth stocks, and next-generation technology stocks, which psychedelic stocks definitely represent.
This will likely put more focus, not only on atai, but the entire psychedelics sector. I would not be surprised if companies such as MindMed (MMEDF) and Cybin (CYBN) also benefit from this. Perhaps, in the future, Ark will also buy these companies.
Hopefully, this is but an opening position, and ARKG continues to buy psychedelic stocks such as atai and MindMed. Ideally, I would also like to see the flagship ETF, ARKK, also invest in psychedelic Stocks.
#CathieWood #ARKG #PsychedelicStocks
Can Ketamine Therapy Be the Solution for Treatment Resistant Depression & Opioid Addiction?
Ketamine therapy is shaping up to be one of the…
